Companies: 10,795·Total market cap: $144.5T
Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc.

LRMRNASDAQHealthcare● Active
$3.10
$-0.07(-2.09%)
Market Cap$265617158
P/E Ratio
52W High$6.42
52W Low$2.22
SEC Filings

Larimar Therapeutics, Inc. (LRMR) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001374690 · LRMR · NASDAQ · as of Jun 8, 2026

Filing snapshot

689
Total Filings
4
Latest Form
2026-05-20
Most Recent
2014
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001374690 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-19
Fiscal Year End
Mar 19, 2026
Accession No.
0001193125-26-115878
Primary Document
lrmr-20251231.htm
Source: data.sec.gov · CIK 0001374690 · Accession 0001193125-26-115878

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-14
8-KCurrent Report
8-K
2026-05-19Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
8-K
2026-05-19
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-14
View
10-QQuarterly Report
10-Q
2026-05-14
View
8-KCurrent Report
8-K
2026-05-14
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-04-30
View
ARSARS
ARS
2026-04-20
View
DEF 14AProxy Statement
DEF 14A
2026-04-20
View
PRE 14APRE 14A
PRE 14A
2026-04-10
View
S-8Employee Stock Plan Registration
S-8
2026-03-19
View
10-KAnnual Report
10-K
2026-03-19
View
8-KCurrent Report
8-K
2026-03-19
View
8-KCurrent Report
8-K
2026-03-09
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-03-02
View
8-KCurrent Report
8-K
2026-02-27
View
424B5424B5
424B5
2026-02-26
View
Showing 1–15 of 460 filingsForm 4 / 144 hidden· 689 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001374690  |  Exchange: NASDAQ · Healthcare

Larimar Therapeutics, Inc. (NASDAQ: LRMR) has submitted 689 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2014. As a Healthcare sector company with CIK 0001374690, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Larimar Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Larimar Therapeutics, Inc. 10-K was filed on 2026-03-19 for fiscal year ending 2026. Historical LRMR 10-K annual reports are available from 2006 through 2026.

Investors researching Larimar Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

LRMR SEC Filings · 8 questions

Larimar Therapeutics, Inc. (LRMR) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 689 filings and access original documents at no cost. Larimar Therapeutics, Inc.'s CIK is 0001374690.

LRMR SEC filingsLarimar Therapeutics, Inc. SEC documentsfind LRMR 10-K